Evidence map›Paper›PMID 40594490›Full record

ArticleScientific reports2025

Identification of STAT3 signaling as a shared pathogenic signature in systemic lupus erythematosus, chronic obstructive pulmonary disease, and asthma.

Arman Mokaram Doust Delkhah

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Arman Mokaram Doust Delkhah, Mashhad, Iran. arman.mokaram@gmail.com.ORCID https://orcid.org/0000-0001-6373-7999

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While patients with systemic lupus erythematosus (SLE) have a higher risk of developing chronic obstructive pulmonary disease (COPD) and asthma, the underlying mechanisms have yet to be elucidated. To this end, by integrating transcriptomic data obtained from blood specimens for each disorder, this study made an effort to investigate shared pathogenic signatures in these three disorders. After identification of shared differentially expressed genes (DEGs), their protein interactions (PPIs) were mapped using a high confidence threshold (0.7). Construction of the networks led to the identification of STAT3 as the central hub gene. Functional enrichment analysis of the shared PPI network of SLE, COPD, and asthma revealed involvement of the shared DEGs in the activation of innate immunity in conjunction with the dysregulation of adaptive immunity, specifically the differentiation of Th1, Th2, and Th17 cells. Moreover, Gene Ontology (GO) analysis highlighted a substantial imbalance between kinase and phosphatase. These observations suggest the STAT3 signaling pathway not only as a pathogenic link between SLE, COPD, and asthma but also as a potential therapeutic target for patients diagnosed with a combination of these disorders.

Indexed as

AsthmaLupus Erythematosus, SystemicPulmonary Disease, Chronic ObstructiveSignal TransductionSTAT3 Transcription FactorGene Expression ProfilingGene OntologyGene Regulatory NetworksHumansProtein Interaction MapsTranscriptomeSTAT3 protein, humanSTAT3 Transcription FactorAsthmaBloodComorbidityCOPDSLESTAT3

Identifiers

PMID40594490
PMCPMC12217132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.